The purpose of this study was to investigate the antitumor effect of eriodictyol on the retinoblastoma Y79 cell line and its potential mechanism of action and to provide a new basis for tumor therapy with the PI3K-Akt signaling pathway as a key molecular target. Here, AKT1 is linked to retinoblastoma.